Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Spyre Therapeutics Inc.
Headquarters: Waltham, MA, United States of America
Website: https://spyretx.com
Year Founded: 2023
Status: Public
Industry Sector: HealthTechnology
CEO: Cameron Turtle, PhD
Number Of Employees: 65
Enterprise Value: $647,535,413
PE Ratio: -5.71
Exchange/Ticker 1: NASDAQ:SYRE
Exchange/Ticker 2: N/A
Latest Market Cap: $1,086,433,664
BioCentury | Nov 23, 2024
Finance
ATB’s €54M series A among largest ever in Belgium
BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Aug 9, 2024
Finance
Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs
Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | Feb 24, 2024
Product Development
Will TL1A be the gateway to precision medicine in inflammation?
Introducing precision medicine to a new disease area faces challenges beyond the biology
BioCentury | Jan 25, 2024
Data Byte
EMA’s CHMP recommended fewer expedited approvals in 2023
The year also hit a new record for applications withdrawn during review
BioCentury | Dec 9, 2023
Deals
Dec. 8 Quick Takes: Kamau debuts with rights to Graphite sickle cell asset
Plus: Spyre boosts balance sheet with $180M PIPE and Pfizer’s bispecific gains EU approval for multiple myeloma
BioCentury | Nov 29, 2023
Management Tracks
Camille Bedrosian named Amylyx CMO
Plus: Cameron Turtle becomes CEO of Spyre, and updates from Ocuphire and Astraveus
BioCentury | Nov 7, 2023
Product Development
Is TL1A the new TNFα?
Interest is rising in autoimmune disease target TL1A. Here’s why
BioCentury | Jun 23, 2023
Finance
How Apogee will test the IPO market’s appetite for preclinical risk
Backed by Fairmount Funds and Venrock and spun out of Paragon, the young start-up has an experienced CFO and is aiming for familiar targets
Items per page:
1 - 10 of 11